Market Cap : 425.86 M | Enterprise Value : 504.51 M | PE Ratio : At Loss | PB Ratio : |
---|
NAS:HLVX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:HLVX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, HilleVax's Enterprise Value is $504.51 Mil. HilleVax does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2021. Therefore, GuruFocus does not calculate HilleVax's EV-to-EBIT at this moment.
The historical rank and industry rank for HilleVax's EV-to-EBIT or its related term are showing as below:
HLVX's EV-to-EBIT is ranked worse thanJoel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. HilleVax's Enterprise Value for the quarter that ended in Dec. 2021 was $0.00 Mil. HilleVax does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2021. Therefore, GuruFocus does not calculate HilleVax's Earnings Yield (Joel Greenblatt) % at this moment.
The historical data trend for HilleVax's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HilleVax Semi-Annual Data | ||
Dec20 | Dec21 | |
EV-to-EBIT | - | - |
For the Biotechnology subindustry, HilleVax's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, HilleVax's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where HilleVax's EV-to-EBIT falls into.
HilleVax's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 504.509 | / | ||
= |
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
HilleVax's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2021 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Dec. 2021 ) | = | EBIT | / | Enterprise Value (Q: Dec. 2021 ) |
= | / | 0 | ||
= | % |
Thank you for viewing the detailed overview of HilleVax's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Fhmls X, L.l.c. | 10 percent owner | 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101 |
Dubin Gary | director | C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109 |
Borkowski Astrid | officer: Chief Medical Officer | C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109 |
Sepulveda Jaime | director | C/O HILLEVAX INC. 75 STATE STREET 100 - #9995 BOSTON MA 02109 |
Takeda Vaccines, Inc. | 10 percent owner | 75 SIDNEY STREET CAMBRIDGE MA 02139 |
Chu Shelley | director | ONE WINTHROP SQUARE SUITE 400 BOSTON MA 02110 |
Silbermann Susan Michele | director | C/O LIANBIO 103 CARNEGIE CENTER DRIVE, SUITE 215 PRINCETON NJ 08540 |
Fhmls X, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101 |
Frazier Life Sciences X, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101 |
Gerberding Julie L. | director | 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 |
Kohli Aditya | director, officer: Chief Operating Officer | C/O PHATHOM PHARMACEUTICALS, INC. 2150 E. LAKE COOK ROAD, SUITE 800 BUFFALO GROVE IL 60089 |
Socks David A | officer: CFO & Chief Business Officer | C/O CADENCE PHARMACEUTICALS, INC. 12481 HIGH BLUFF DRIVE, SUITE 200 SAN DIEGO CA 92130 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668 |
Hershberg Robert | director, officer: President and CEO | 3005 FIRST AVENUE SEATTLE WA 98121 |
Topper James N | 10 percent owner | 550 HAMILTON AVENUE, SUITE 100 PALO ALTO CA 94301 |
From GuruFocus
Other Sources
By tipranks.com 2022-05-25